Diagnosing and managing patients with drug hypersensitivity

Area of Science:

• Clinical Immunology
• Pharmacovigilance
• Drug Safety

Background:

• Drug hypersensitivity diagnosis is challenging due to unclear reaction boundaries.
• Distinguishing predictable (Type A) from hypersensitivity (Type B) reactions is difficult.
• Adverse drug reactions are influenced by genetics, infections, and other therapies.

Purpose of the Study:

• To review the diagnosis and management of IgE-mediated immediate drug hypersensitivity reactions (IDHRs) and non-immediate drug hypersensitivity reactions (NIDHRs).

Main Methods:

• Review of diagnostic challenges including clinical history, skin tests, in vitro tests, and drug provocation tests.
• Discussion of management strategies for immediate and non-immediate drug hypersensitivity.
• Exploration of current diagnostic disparities between Europe and the United States.

Main Results:

• Clinical history is often the primary diagnostic tool, though tests can be unreliable or unavailable.
• Drug provocation tests carry risks, especially in severe cutaneous reactions.
• Management requires avoiding the suspected drug and evaluating safe alternatives.

Conclusions:

• Patients with a history of drug hypersensitivity must avoid the implicated drug.
• Medical surveillance is crucial when assessing tolerance to alternative medications.
• Genetic testing and patient documentation are recommended for preventing future exposures.